7 Reasons Why pvindia March Forum was a Resounding Success

The pvindia event brought together professionals and experts from across pharmacovigilance companies in India and across the world. With its insightful sessions and dynamic networking opportunities, pvindia held in March 2023, emerged as a resounding success, discussing the latest on drug safety pharmacovigilance and looking toward the future. Speakers at the event included Satish Sethi, Head Global Pharmacovigilance operations and SERM surveillance operations at Glenmark Pharmaceuticals, Dr Girish Sane, Section Head PV, Macleods Pharmaceuticals Ltd., Rahul Nair, Director, Arcolab Private Limited, Dr Nilay Modi, Senior Manager- Pharmacovigilance, Amneal Pharmaceuticals, and Hellen Zhang, Executive Director, Global Patient Safety, BeiGene.

Ben Parsons who led the meeting had this to say about the PV India March 2023 forum


“I would like to thank the participants and especially our expert panellists for the insightful and thought provoking discussions on the future of PV.”
Ben Parsons,
Senior Management Consultant and pvconnect Lead
Navitas Life Sciences

In this blog, we will explore seven reasons why pvindia march forum proved to be an invaluable platform for knowledge sharing, collaboration, and growth.

1) Thought-Provoking Sessions: pvindia offered a diverse range of thought-provoking sessions, featuring industry leaders, and renowned experts. The carefully curated agenda covered topics such as the reality of GVP China expectations, and current and future thinking in ICSR management and Safety Science. The sessions fostered in-depth discussions, providing attendees with valuable insights and actionable takeaways.

58 Attendees

35 companies

Key Takeaways

  • GVP Guidance by NMPA in China, key difference compared to
  • Future of safety science: data science, talent retention and operational excellence
  • ICSR management: outsourcing, automation and collaboration

2) Group Discussions: One of the key highlights of pvindia was the ample opportunities it provided to discuss key topics. The event brought together professionals from various domains of pharmacovigilance, including pharmaceutical companies, and technology providers. This facilitated meaningful discussions, fostering innovative thought process, and enabling participants to build a stronger understanding of current trends.

IDMP

3) Focus on the Future of PV: pvindia emphasized the importance of understanding the future of PV. Renowned industry experts shared their perspectives on evolving regulations and guidelines, and other external and internal drivers that are shaping the future directions. This focus on future trends and landscape ensured that attendees gained a thorough understanding of the latest requirements and best practices, enabling them to navigate the challenges and opportunities effectively.

IDMP

4) Engaging Panel Discussions: pvindia event featured engaging panel discussions that encouraged active participation and practical learning. These discussions provided a ring side view of the safety science landscape, providing an enhanced overall learning experience.

Panel discussion:

what does the future hold for Safety Science? How can we shift to benefit-risk management?

  • What does your current Safety Science organization look like?
    • Aggregate Reporting / Signal Mgt / Risk Management
    • Functions / reporting lines / responsibilities
  • What do you see as the future needs for your Safety Science Organisation?
    • What are your current challenges? What are the opportunities?
    • What skills and capabilities are required?
  • How are you gearing up for the future?
    • How are you building capability? People / process / tools
    • How can we continue to shift focus to benefit-risk management?

5) Showcasing Automation for Individual Case Study Report(ICSR): The event served as a platform to look closely at automation for ISCR. ICSR volumes continue to increase year on year, with high proportion of ICSRs from literature, legal and Health Authority sources. From outsourcing and process optimization to automation, pvindia provided attendees with insights into the latest tools and technologies methods transforming the industry. Interactive discussions allowed participants to identify first hand how various methods could improve ICSR processing.

What does the future hold for ICSR? How can we how can we simplify to navigate the increasing volumes?

Approaches

  • Cross-functional capabilities, better innovation
  • Identify certain areas where automation can be set – critical was literature
  • Annual volumes needed to be handled in 3 months, increase due to literature and litigation
  • Currently working on AI, ML and NLP processing to handle the increase
  • Making sure you run tests to check for accuracy
  • Resources: the literature search is still done manual, articles are uploaded, and a quality check is done – comparison of manual vs automated
  • Automation has been proven to be helpful, manual effort reduced
  • Use of call centers, social media – IT support partners
  • Building database to help with repeated questions
  • Identify certain areas where automation can be set – critical was literature
  • Working with vendor to crate a customized software: testing face has been completed, validation will start in Apr
  • Dashboard can get data from Argus, can see cases pending
  • All cases received on a mailbox and then onto Argus
  • Highly validated process, high compliance (98%)
  • All PV activity in-house (25 team members), US based but global expansion to 59 countries

6) Hotbed for Collaboration and Partnerships:

pvindia served as a catalyst for collaboration and partnerships within the pharmacovigilance ecosystem. By bringing together stakeholders from diverse backgrounds, the event facilitated discussions and collaborations that can lead to innovative solutions, improved processes, and enhanced patient safety. Attendees had the opportunity to explore potential partnerships and form synergies that can drive the industry forward.

7) Excellent Attendee Engagement:

Recognizing the crucial role of the pvindia event placed a strong emphasis on incorporating expert perspectives. Industry leaders shared their experiences, challenges, and expectations, fostering great learning in the field of safety science. This focus on participant engagement helped attendees gain insights into real-world experiences and reinforced the importance of patient safety in pharmacovigilance. The end result? Attendees loved it!<#03184f/p>

pvindia value rating survey results: 84% satisfaction

58 attendees from 35 companies

The pvindia event organized by Navitas Life Sciences was a tremendous success, offering a plethora of benefits to attendees. From thought-provoking sessions and networking opportunities to technological advancements and safety-centric approaches, pvindia a showcased the remarkable strides being made in pharmacovigilance in India and globally. By fostering collaboration, and recognizing latest trends, pvindia played a pivotal role in advancing drug safety in the ecosystem.

What are you waiting for?

Register for the pvindia 15th Autumn Forum

Date: 5 October 2023

Venue: ITC Maratha, Mumbai

Lead by: Latika Sharma and Ben Parsons

Navigating combination products for patient safety organizations

Our PV and Medtech Networks Thought Lead, Dr Latika Sharma, MBBS, MD, presented at Sidley’s mtlegal Spring Biannual Meeting which took place in Belgium on 30 March 2023.

Latika’s session explored ‘Navigating Combination Products for Patient Safety Organizations’ with the session addressing:

  • Combination products – the rising meteor
  • Combination products in pharma – complexity and challenges
  • Safety obligations – device vigilance and pharmacovigilance
  • Considerations for the future safety organizations

To learn more about our services and solutions, reach out to us at This email address is being protected from spambots. You need JavaScript enabled to view it.

To register for the event, please email This email address is being protected from spambots. You need JavaScript enabled to view it.